These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. Global and Regional Brain Assessment with Quantitative MR Imaging in Patients with Prior Exposure to Linear Gadolinium-based Contrast Agents. Kuno H; Jara H; Buch K; Qureshi MM; Chapman MN; Sakai O Radiology; 2017 Apr; 283(1):195-204. PubMed ID: 27797676 [TBL] [Abstract][Full Text] [Related]
70. Brain MRI and clinical exam findings in women with multiple gadolinium-based contrast agent (GBCA) exposures due to screening breast MRIs. Myers KS; Yousem DM; Mills KA; Gad K; Niri SG; Bienko N; Munro CA Clin Imaging; 2022 Dec; 92():57-62. PubMed ID: 36202017 [TBL] [Abstract][Full Text] [Related]
71. Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration? Wake N; Chandarana H; Rusinek H; Fujimoto K; Moy L; Sodickson DK; Kim SG Magn Reson Imaging; 2018 Oct; 52():16-23. PubMed ID: 29777820 [TBL] [Abstract][Full Text] [Related]
72. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model. Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804 [TBL] [Abstract][Full Text] [Related]
73. Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. Wang C; Yin FF; Kirkpatrick JP; Chang Z Technol Cancer Res Treat; 2017 Aug; 16(4):446-460. PubMed ID: 27215931 [TBL] [Abstract][Full Text] [Related]
74. Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer: A feasibility study. Jena A; Taneja S; Singh A; Negi P; Mehta SB; Sarin R Eur J Radiol; 2017 Jan; 86():261-266. PubMed ID: 28027758 [TBL] [Abstract][Full Text] [Related]
75. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading. Su CQ; Lu SS; Han QY; Zhou MD; Hong XN Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590 [TBL] [Abstract][Full Text] [Related]
76. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature. Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567 [TBL] [Abstract][Full Text] [Related]
77. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Chidambaram S; Pannullo SC; Roytman M; Pisapia DJ; Liechty B; Magge RS; Ramakrishna R; Stieg PE; Schwartz TH; Ivanidze J Neurosurg Focus; 2019 Jun; 46(6):E10. PubMed ID: 31153141 [TBL] [Abstract][Full Text] [Related]
78. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718 [TBL] [Abstract][Full Text] [Related]
79. Quantitative assessment of gadolinium deposition in dentate nucleus using quantitative susceptibility mapping. Hinoda T; Fushimi Y; Okada T; Arakawa Y; Liu C; Yamamoto A; Okada T; Yoshida K; Miyamoto S; Togashi K J Magn Reson Imaging; 2017 May; 45(5):1352-1358. PubMed ID: 27664936 [TBL] [Abstract][Full Text] [Related]
80. The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging. Jia ZZ; Gu HM; Zhou XJ; Shi JL; Li MD; Zhou GF; Wu XH Eur J Radiol; 2015 Sep; 84(9):1805-9. PubMed ID: 26066470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]